

Hiroji Iwata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2510690/publications.pdf>

Version: 2024-02-01

81
papers

19,826
citations

101543

36
h-index

58581

82
g-index

87
all docs

87
docs citations

87
times ranked

18128
citing authors

#	ARTICLE	IF	CITATIONS
1	The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. <i>Breast Cancer</i> , 2022, 29, 234-241.	2.9	90
2	Oncology care providers' awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: a nationwide cross-sectional web-based survey. <i>Supportive Care in Cancer</i> , 2022, 30, 3105-3118.	2.2	2
3	Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458.	1.6	25
4	Management of breast cancer in older patients. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 682-689.	1.3	3
5	Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 253-262.	2.2	0
6	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	27.0	474
7	Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1962-1963.	1.6	3
8	Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1239-1247.	1.9	6
9	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. <i>Clinical Cancer Research</i> , 2022, 28, 3433-3442.	7.0	65
10	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	6.3	171
11	Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. <i>Breast Cancer</i> , 2021, 28, 1087-1095.	2.9	2
12	Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial. <i>BMC Cancer</i> , 2021, 21, 548.	2.6	8
13	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	6.3	83
14	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. <i>Oncologist</i> , 2021, 26, e1143-e1155.	3.7	15
15	Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	1.6	23
16	Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462.	1.6	16
17	Current Status of Advance Care Planning and End-of-Life Communication for Patients with Advanced and Metastatic Breast Cancer. <i>Oncologist</i> , 2021, 26, e686-e693.	3.7	10
18	Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2179-2193.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 91-100.	2.5	16
20	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
21	The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. <i>Breast Cancer</i> , 2020, 27, 1-3.	2.9	14
22	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	10.7	826
23	Reply to T.J.A. Dekker. <i>Journal of Clinical Oncology</i> , 2020, 38, 3351-3352.	1.6	0
24	Study protocol for a nationwide questionnaire survey of physical activity among breast cancer survivors in Japan. <i>BMJ Open</i> , 2020, 10, e032871.	1.9	4
25	Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752.	1.6	50
26	Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction. <i>Breast Cancer</i> , 2020, 27, 716-723.	2.9	5
27	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low Expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1887-1896.	1.6	465
28	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. <i>Breast Cancer</i> , 2020, 27, 631-641.	2.9	6
29	The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. <i>Breast Cancer</i> , 2020, 27, 322-331.	2.9	47
30	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 688-701.	9.4	212
31	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1000-1000.	1.6	135
32	Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy. <i>Breast Journal</i> , 2019, 25, 202-206.	1.0	4
33	Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. <i>Breast Cancer</i> , 2019, 26, 637-650.	2.9	8
34	A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1320-1327.	2.2	1
35	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1929-1940.	27.0	1,582
36	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 827-836.	10.7	154

#	ARTICLE	IF	CITATIONS
37	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 816-826.	10.7	252
38	Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 262-273.	2.2	39
39	Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 274-287.	2.2	43
40	Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 123-133.	2.5	77
41	Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. <i>Cancer Science</i> , 2018, 109, 803-813.	3.9	29
42	Clinical development of CDK4/6 inhibitor for breast cancer. <i>Breast Cancer</i> , 2018, 25, 402-406.	2.9	29
43	Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma. <i>Breast Cancer</i> , 2018, 25, 560-565.	2.9	13
44	Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan. <i>Breast Cancer</i> , 2018, 25, 60-67.	2.9	3
45	Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study. <i>Breast Cancer</i> , 2018, 25, 108-117.	2.9	4
46	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2018, 36, 741-748.	1.6	110
47	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	27.0	3,097
48	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1926-1936.	27.0	805
49	Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?. <i>Chinese Clinical Oncology</i> , 2018, 7, 23-23.	1.2	22
50	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 501-510.	2.5	13
51	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	10.7	427
52	Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 473-482.	2.5	7
53	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
54	PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients. <i>Journal of Global Oncology</i> , 2017, 3, 289-303.	0.5	94

#	ARTICLE	IF	CITATIONS
55	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	10.7	1,344
56	Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1088-1094.	1.3	7
57	Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). <i>Oncologist</i> , 2016, 21, 1165-1175.	3.7	183
58	Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. <i>BMC Cancer</i> , 2016, 16, 248.	2.6	78
59	Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy. <i>Breast Cancer</i> , 2016, 23, 190-194.	2.9	18
60	Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	27.0	1,239
61	Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 277-284.	2.5	32
62	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2015, 20, 709-722.	2.2	7
63	Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. <i>Breast Cancer</i> , 2015, 22, 192-200.	2.9	7
64	Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. <i>Breast Cancer</i> , 2015, 22, 486-495.	2.9	29
65	Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. <i>Breast Cancer</i> , 2015, 22, 586-595.	2.9	19
66	Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. <i>Breast Cancer</i> , 2014, 21, 703-714.	2.9	57
67	Brain Metastases in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1133-1140.	1.3	26
68	Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 607-613.	2.2	54
69	A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2013, 18, 621-628.	2.2	19
70	The Transition of Breast Cancer Treatment and Japan Clinical Oncology Group Research Over Two Decades. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 14-20.	1.3	2
71	Future treatment strategies for metastatic breast cancer: curable or incurable?. <i>Breast Cancer</i> , 2012, 19, 200-205.	2.9	26
72	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. <i>Cancer Science</i> , 2011, 102, 858-865.	3.9	44

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept. <i>Breast Cancer</i> , 2011, 18, 92-97.	2.9	10
74	Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 709-712.	1.3	38
75	Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 867-875.	1.3	53
76	Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. <i>Breast Cancer</i> , 2010, 17, 199-204.	2.9	123
77	Neo(adjuvant) trastuzumab treatment: current perspectives. <i>Breast Cancer</i> , 2009, 16, 288-294.	2.9	2
78	Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 531-539.	2.5	97
79	Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 3859-3865.	1.6	505
80	Perspective of trastuzumab treatment. <i>Breast Cancer</i> , 2007, 14, 150-155.	2.9	7
81	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1659-1672.	27.0	4,601